新兴市场目前占据了全球医疗技术行业收入的1/4,但随着中国和印度市场的快速增长,到2022年新兴市场将占到1/3。迈瑞和华大基因两家中国公司,以及印度的Transasia Bio-Medicals,将会成为业内知名企业。成熟的医疗技术企业如果忽视新兴市场企业的崛起,将面临失去市场份额的风险,或者只能被限制在高端市场。 Emerging markets now account for about a quarter of the global medical technology industry, but with the rapid growth in China and India, emerging markets will account for one-third by 2022. Two Chinese companies Mindray and Huada Gene, as well as India’s Transasia Bio-Medicals, will become well-known companies in the industry. Mature medical technology companies, which ignore the rise of emerging market firms, are at risk of losing market share or can only be confined to the high-end market.